Designing a First-in-Human Study of a Systemically Administered AAV Micro-Dystrophin Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy: Scientific and Regulatory Rationale and Phase 1 Protocol Synopsis

A single systemic infusion of an AAV vector at doses near 10 to the power of 14 vector genomes per kilogram cannot be undone, and the vector load, not the body surface area, determines most of its risks. This article develops the scientific and regulatory rationale and a complete protocol synopsis for a hypothetical first-in-human study of a systemically administered AAV micro-dystrophin gene therapy in ambulatory boys aged 4 to under 8 years with Duchenne muscular dystrophy. It proposes an open-label, non-randomized, single-ascending-dose study of 12 participants in two dose cohorts of four (6.6 x 10 to the power of 13 and 1.33 x 10 to the power of 14 vector genomes per kilogram) with an optional third cohort, sentinel dosing with a 14-day observation, mandatory pre-dose antibody screening, prophylactic corticosteroids, intensive weekly liver monitoring for 12 weeks, explicit hepatic and immune stopping rules, and long-term follow-up of at least 5 years. Micro-dystrophin expression is a co-primary biological endpoint and motor function is exploratory. All nonclinical values and doses are illustrative assumptions, and the article treats class-level risks as design inputs and not as findings about any product.Keywords: first-in-human; AAV gene therapy; micro-dystrophin; Duchenne muscular dystrophy; pediatric Phase 1; hepatic monitoring; long-term follow-up

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24426593
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Designing a First-in-Human Study of a Systemically Administered AAV Micro-Dystrophin Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy: Scientific and Regulatory Rationale and Phase 1 Protocol Synopsis

Kishan Rajput, Peivand Pirouzi, Pruthvirajsinh Sindha, Sukhpreet Singh Maan et al.
Zenodo (CERN European Organization for Nuclear Research)
Virus-based gene therapy research
article

Designing a First-in-Human Study of a Systemically Administered AAV Micro-Dystrophin Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy: Scientific and Regulatory Rationale and Phase 1 Protocol Synopsis

Kishan Rajput, Peivand Pirouzi, Pruthvirajsinh Sindha, Sukhpreet Singh Maan, Vraj Modi
article en

Abstract

A single systemic infusion of an AAV vector at doses near 10 to the power of 14 vector genomes per kilogram cannot be undone, and the vector load, not the body surface area, determines most of its risks. This article develops the scientific and regulatory rationale and a complete protocol synopsis for a hypothetical first-in-human study of a systemically administered AAV micro-dystrophin gene therapy in ambulatory boys aged 4 to under 8 years with Duchenne muscular dystrophy. It proposes an open-label, non-randomized, single-ascending-dose study of 12 participants in two dose cohorts of four (6.6 x 10 to the power of 13 and 1.33 x 10 to the power of 14 vector genomes per kilogram) with an optional third cohort, sentinel dosing with a 14-day observation, mandatory pre-dose antibody screening, prophylactic corticosteroids, intensive weekly liver monitoring for 12 weeks, explicit hepatic and immune stopping rules, and long-term follow-up of at least 5 years. Micro-dystrophin expression is a co-primary biological endpoint and motor function is exploratory. All nonclinical values and doses are illustrative assumptions, and the article treats class-level risks as design inputs and not as findings about any product.Keywords: first-in-human; AAV gene therapy; micro-dystrophin; Duchenne muscular dystrophy; pediatric Phase 1; hepatic monitoring; long-term follow-up

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon